Introduction {#s1}
============

Failure of the kidneys is associated with the gradual retention of a myriad of solutes [@pone.0076838-Vanholder1], causing an endogenous intoxication and failure of almost all organ systems [@pone.0076838-Vanholder2], [@pone.0076838-Meyer1]. Dialysis aims at removing those solutes, resulting in a decrease of their concentration and hence also their biological toxicity.

Quantification of the removal of these toxins may offer a useful tool to evaluate the adequacy of a given approach, but might also lead to misconceptions, e.g. by abandoning attempts to further improve a removal strategy once a set target is reached. Traditionally, Kt/V~urea~ is the marker of dialysis adequacy that is most widely used on a regular basis. In some countries, reaching a threshold Kt/V~urea~ is even a prerequisite for reimbursement of dialysis [@pone.0076838-Vanholder3].

When considering observational data, one cannot deny that the introduction of Kt/V~urea~ in 1985 helped to gradually improve survival of the dialysis population [@pone.0076838-Gotch1]--[@pone.0076838-Saran1]. The parameter was however developed in an era when dialysis was almost exclusively performed over relatively short sessions with small pore dialyzers [@pone.0076838-Sirich1]. Many strategic modifications have meanwhile been introduced, such as large pore membranes, convection, frequent dialysis and extended dialysis. All these alternative strategies enhance solute removal [@pone.0076838-Basile1]--[@pone.0076838-Walsh1] and have been associated with improved outcome [@pone.0076838-Rocco1], [@pone.0076838-Ayus1]--[@pone.0076838-Santoro1], but do not necessarily increase Kt/V~urea~ [@pone.0076838-Basile1], [@pone.0076838-Eloot1], [@pone.0076838-Locatelli1], [@pone.0076838-Santoro1]. Also the number of known uremic toxins has extended [@pone.0076838-Duranton1], [@pone.0076838-Vanholder4], mostly with compounds that are difficult to remove by standard dialysis.

In two recent studies, we demonstrated in CKD patients not yet on dialysis that estimated GFR (eGFR), as the main currently used marker of renal function, was barely and inconsistently associated with concentrations of uremic toxins, although the latter are associated with organ dysfunction [@pone.0076838-Eloot3], [@pone.0076838-Neirynck1]. This divergence was attributed to a greater impact on uremic solute concentration by factors other than GFR, such as diet, intestinal generation, metabolism and tubular secretion [@pone.0076838-Vanholder5].

Thus, the question could be raised in how far this would be true as well for the main marker of dialysis adequacy Kt/V~urea~. Although Kt/V~urea~ is mathematically related to the concentration change during dialysis, one could assume that keeping this parameter at a higher threshold would result in a decrease of uremic solute concentration as a consequence of more efficient removal, also before dialysis.

An additional asset of performing this type of study in hemodialysis, is that in this setting, it is quite easy to assess objectively dietary protein intake, one of the potentially impacting factors [@pone.0076838-Schepers1]. Remarkably enough, this question has to the best of our knowledge never been studied, although a recent review pointed to the theoretical possibility that Kt/V~urea~ would not be an accurate marker for uremic solute removal and retention [@pone.0076838-Meyer2].

Therefore, in this study we want to clarify: 1/whether Kt/V~urea~ is representative for the concentration of a broad array of uremic toxins in patients on hemodialysis; 2/whether there is a difference in uremic toxin concentrations depending on other patient characteristics such as age, body weight, protein equivalent of nitrogen appearance, residual renal function, dialysis vintage, gender, and diabetes mellitus.

Patients and Methods {#s2}
====================

Ethics Statement {#s2a}
----------------

The study was approved by the local Ethics Committee (Ethical Committee, Ghent University Hospital, Ghent, Belgium) and performed in accordance to the Declaration of Helsinki. Written informed consent was obtained from all participants.

Patients {#s2b}
--------

All chronic hemodialysis patients, older than 18 years, with a residual renal function lower than 10 mL/min, and dialyzed in our centre during the day, were considered for inclusion. Patients were on maintenance hemodialysis for at least three months during which the same hemodialyzer, dialysis duration, blood and dialysate flows, convective strategy, and vascular access had been applied. Dialysis dose, expressed as Kt/V~urea~ is calculated monthly according to the single-pool Daugirdas formula [@pone.0076838-Daugirdas1] to check accordance to the EBPG [@pone.0076838-Section1], and is only adapted if the value goes below threshold. The general exclusion criteria were active infection, pregnancy, unstable condition, and vascular access problems.

Sampling and data collection {#s2c}
----------------------------

Predialysis blood samples were taken during a midweek session, immediately centrifuged (3000 rpm corresponding to 1250 g), aliquoted, and stored at −80°C until analysis. Postdialysis blood samples, as needed for the calculation of Kt/V~urea~ and PNA, were taken immediately after discontinuation of the dialysis session after slowing the blood pump to 100 mL/min during 15 s.

Urea \[molecular weight MW: 60D\] and creatinine (Crea) \[MW: 113D\] were measured by standard laboratory methods.

Different solutes, most of them protein bound, were determined by high performance liquid chromatography (HPLC): uric acid (UA) \[168D\], hippuric acid (HA) \[179D, protein binding (PB)∼50%\], 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) \[240D - PB∼100%\], indoxyl sulfate (IS) \[213D - PB∼90%\], indole acetic acid (IAA) \[175D - PB∼65%\], *p*-cresylsulfate (PCS) \[187D - PB∼95%\], and *p*-cresylglucuronide (PCG) \[284D - PB∼10%\]. To determine the total fraction, serum samples were first deproteinized by heat denaturation [@pone.0076838-Vanholder6] and analyses were performed by reverse-phase HPLC. IS and IAA (excitation λ~ex~:280 nm; emission λ~em~:340 nm) and PCS and PCG (λ~ex~:265 nm; λ~em~:290 nm) were determined by fluorescence analysis, and HA and CMPF were analyzed by UV detection at 254 nm [@pone.0076838-Fagugli2]. Free fractions were determined according to Fagugli et al [@pone.0076838-Fagugli2].

ELISA kits manufactured by DLD Diagnostika GmbH (Hamburg, Germany) were used for measuring asymmetric dimethylarginine (ADMA) \[202D\], symmetric dimethylarginine (SDMA) \[202D\] after acylation. For beta-2-microglobulin (β~2~M) \[11.8 kD\], ELISA kits of Orgentec Diagnostika GmbH (Mainz, Germany) were used.

For each patient, the following additional parameters were registered: age, gender, body weight (BW), presence of diabetes mellitus (DM), dialysis vintage, and medication, while Kt/V~urea~, residual renal function (RRF), and protein equivalent of nitrogen appearance (PNA) were calculated as explained below.

Calculations {#s2d}
------------

Since the single treatment dose as measured during a midweek dialysis session does not reflect the average clearance both by exogenous hemodialysis and endogenous residual renal clearance, we calculated weekly Kt/V~urea~ accounting for ultrafiltration and residual renal function according to Daugirdas et al [@pone.0076838-Daugirdas2]:with F the number of dialysis sessions per week, K~ru~ the residual renal urea clearance (mL/min), UF~w~ the weekly fluid removal (L), V the urea distribution volume (L) as calculated according to Daugirdas and Smye [@pone.0076838-Daugirdas3], and S the standard Kt/V according to Leypoldt:with t the treatment time (min), and eKt/V calculated according to [@pone.0076838-Tattersall1]:And spKt/V calculated according to Daugirdas et al [@pone.0076838-Daugirdas1]:with BUN~pre~ and BUN~post~ the pre and post dialysis Blood Urea Nitrogen concentration, UF the ultrafiltration volume, and BW the post dialysis body weight.

Residual Renal Function (RRF) was calculated as the arithmetic mean of the creatinine and urea clearance (Cl~Crea~ and Cl~urea~, respectively):with:with C~urine~ and V~urine~ (mL) the concentration and volume of the urine as collected during the interdialytic period Δt~inter~ (h), and C~start~ and C~end~ the blood concentrations at the start and end of the interdialytic period. Herewith, C~start~ was corrected for the post-dialysis rebound as [@pone.0076838-Section2]:With C~pre~ and C~post~ the pre and immediate post-dialysis concentrations, and R the rebound time, i.e. 35 min for urea and 70 min for Crea.

Finally, the Protein equivalent of Nitrogen Appearance (PNA) at midweek was calculated according to the K/DOQI and EBPG [@pone.0076838-National1], [@pone.0076838-Fouque1]:

Statistical analyses {#s2e}
--------------------

For the patient characteristics age, BW, Kt/V~urea~, PNA, and dialysis vintage, the median and 25^th^ and 75^th^ percentile were calculated and, per characteristic, patients were divided into four groups according to quartiles. Since the median of RRF was zero, the four groups for this parameter were not defined by quartiles but consisted of one group to which all anuric patients were selected (n = 40), whereas the remaining non-anuric patients were distributed in tertiles (n = 10--11 each). For gender and DM, patients were divided in two groups according to male/female and DM/non DM. With these data, non-parametric analysis of variance (Kruskal-Wallis) tests were performed to check potential differences in uremic toxin concentrations among the groups.

Furthermore, correlations (Spearman) were evaluated between uremic toxin concentrations and the different studied characteristics; finally, multifactor analyses per solute were performed.

The data of patients taking allopurinol were excluded from the analysis considering uric acid.

Data are expressed as mean ± standard deviation for normal distributions, or as medians with the 25^th^ and 75^th^ percentiles for non normal distributions.

P\<0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS Statistics 19 (SPSS Inc, Chicago, IL) for Windows (Microsoft Corp, Redmond, WA).

Results {#s3}
=======

Seventy-four chronic hemodialysis patients fulfilled the inclusion criteria. Two of them declined written consent, and 1 patient had an interdialytic interval of 2.5 days at midweek instead of 1.5 days. The 71 chronic hemodialysis patients included were on thrice weekly hemodialysis for 38.0 (19.5--61.5) months: 26/45 females/males, 28 diabetes mellitus, 31 with RRF, age 72 (63.0--80.0) years, body weight 69.0 (61.3--78.8) kg, weekly Kt/V~urea~ 2.43 (2.28--2.63), and PNA 0.83 (0.74--1.01) g/kg/day ([Table 1](#pone-0076838-t001){ref-type="table"}).

10.1371/journal.pone.0076838.t001

###### Patient characteristics and Kt/V values.

![](pone.0076838.t001){#pone-0076838-t001-1}

                               Median (25^th^--75^th^ percentile)[\*](#nt101){ref-type="table-fn"}
  --------------------------- ---------------------------------------------------------------------
  Gender (female/male)                                        26/45
  DM (yes/no)                                                 28/43
  RRF (yes/no)                                                31/40
  Allopurinol (yes/no)                                        7/64
  Age (years)                                           72.0 (63.0--80.0)
  BW (kg)                                               69.0 (61.3--78.8)
  spKt/V                                                1.62 (1.45--1.89)
  eKt/V                                                 1.43 (1.28--1.66)
  weekly Kt/V                                           2.43 (2.28--2.63)
  PNA (g/kg/day)                                        0.83 (0.74--1.01)
  Dialysis vintage (months)                             38.0 (19.5--61.5)

if applicable.

DM: diabetes mellitus, BW: body weight, RRF: residual renal function, PNA: protein equivalent of nitrogen appearance.

Our patients were routinely dialyzed for 245±18 min, with a blood flow of 321±37 mL/min (Q~B~ range 220--350 mL/min) and Q~D~ = 500 mL/min in hemodialysis mode with either an FX8 (Fresenius Medical Care, Germany) (n = 5), or Evodial (Gambro, Sweden) (n = 1) dialyzer, or in postdilution hemodiafiltration mode with either an FX800 (Fresenius Medical Care, Germany) (n = 41), Phylter 17SD (Bellco, Italy) (n = 7), Xenium 210 (Baxter, USA) (n = 6), PHF (Bellco, Italy) (n = 4), Polyflux 170H (Gambro, Sweden) (n = 4), or Surflux 170UH (Nipro, Japan) (n = 3) dialyzer. All patients had a permanent vascular access: i.e. 42 fistulas and 29 tunneled central venous catheters.

An overview of the measured predialysis concentrations of uremic solutes is given in [Table 2](#pone-0076838-t002){ref-type="table"}. The percentage differences between minimum and maximum concentrations among the patients ranged from 72.0 (UA) to 99.5% (total and free PCG) ([Table 2](#pone-0076838-t002){ref-type="table"}); normalizing concentrations to Kt/V~urea~ resulted in the same percentage differences between the minimum and maximum values (data not shown).

10.1371/journal.pone.0076838.t002

###### Uremic toxin concentrations.
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              median (25^th^--75^th^p)   \[(75^th^-25^th^)/75^th^\]·100    min - max    \[(max-min)/max\]·100
  ---------- -------------------------- -------------------------------- ------------- -----------------------
  urea           0.90 (0.71--1.06)                    33.5                0.18--1.88            90.4
  Crea           7.19 (5.77--9.01)                    36.0                3.35--14.9            80.4
  ADMA           1.00 (0.84--1.18)                    28.2                0.51--1.93            73.6
  SDMA           2.08 (1.73--2.48)                    30.3                0.77--3.79            79.7
  UA             6.53 (5.62--7.06)                    20.3                2.55--9.11            72.0
  β~2~M          39.4 (28.5--48.1)                    40.8                13.9--96.3            89.6
  HA             2.94 (1.47--5.64)                    74.0                0.24--14.21           98.3
  IS             1.80 (1.27--2.77)                    54.4                0.29--5.75            97.7
  IAA            0.18 (0.13--0.23)                    42.7                0.07--0.73            90.9
  PCS            2.94 (1.73--4.36)                    60.2                0.06--7.53            99.2
  PCG            0.49 (0.18--0.89)                    79.8                0.02--3.94            99.5
  CMPF           0.38 (0.20--0.61)                    68.0                0.06--1.37            95.8
  Free HA        1.65 (0.70--3.32)                    79.0                0.13--9.09            98.6
  Free IS        0.11 (0.06--0.23)                    72.4                0.02--0.72            97.8
  Free IAA       0.06 (0.04--0.07)                    48.1                0.02--0.22            91.2
  Free PCS       0.18 (0.11--0.33)                    66.4                0.04--0.66            94.7
  Free PCG       0.48 (0.17--0.86)                    80.1                0.02--3.59            99.5

mg/dL, except urea in g/L, β~2~M in µg/mL, and ADMA and SDMA in µmol/L.

Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric dimethylarginine, UA: uric acid, β~2~M: beta-2-microglobulin, HA: hippuric acid, IS: indoxyl sulfate, IAA: indole acetic acid, PCS: *p*-cresylsulfate, PCG: *p*-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.

[Table 3](#pone-0076838-t003){ref-type="table"} shows the P-values of the Kruskal-Wallis tests for the concentrations under study if patient characteristics were separated in quartiles or dichotomically. The main characteristics associated with a significant difference of solute concentrations were PNA and RRF ([Table 3](#pone-0076838-t003){ref-type="table"} and [Figure 1](#pone-0076838-g001){ref-type="fig"}). For Kt/V~urea~ no single significant difference was found.

![Box plots of quartiles and correlations of different solute concentrations versus Kt/V, PNA, and RRF: urea in g/L (panels A, B, and C), β~2~M in µg/mL (panels D, E, and F), HA in mg/dL (panels G, H, and I), and free PCS in mg/dL (panels J, K, and L).\
β~2~M: beta-2-microglobulin, HA: hippuric acid, PCS: *p-*cresylsulfate, PNA: protein equivalent of nitrogen appearance, RRF: residual renal function.](pone.0076838.g001){#pone-0076838-g001}

10.1371/journal.pone.0076838.t003

###### P-values of comparison between concentrations for characteristics as divided in quartiles or dichotomically.

![](pone.0076838.t003){#pone-0076838-t003-3}

                 Age         BW       Kt/V        PNA           RRF        vintage     gender        DM
  ---------- ----------- ----------- ------- ------------- ------------- ----------- ----------- -----------
  urea          0.097       0.116     0.478   **\<0.001**      0.265        0.219       0.310       0.728
  Crea          0.129     **0.015**   0.339    **0.027**       0.345        0.441     **0.004**     0.842
  ADMA          0.616       0.458     0.396      0.848         0.337        0.683       0.492       0.814
  SDMA          0.408       0.891     0.297      0.548         0.196        0.794       0.797       0.668
  UA          **0.002**   **0.026**   0.097    **0.004**       0.240      **0.026**   **0.025**     0.171
  β~2~M         0.898       0.666     0.585      0.607      **\<0.001**     0.644       0.346       0.916
  HA            0.539       0.577     0.602    **0.036**     **0.004**      0.268       0.247       0.378
  IS            0.850       0.462     0.340      0.261         0.159        0.664       0.839       0.259
  IAA           0.678       0.251     0.583      0.203         0.089        0.959       0.437       0.402
  PCS           0.283       0.698     0.809    **0.001**       0.815        0.739       0.452       0.312
  PCG           0.230       0.786     0.391      0.067       **0.041**      0.766       0.273       0.291
  CMPF          0.065       0.537     0.316      0.464         0.073        0.984       0.865       0.106
  Free HA       0.491       0.580     0.629      0.092       **0.002**      0.181       0.277       0.384
  Free IS       0.505       0.605     0.620      0.266       **0.006**      0.772       0.976       0.110
  Free IAA      0.633       0.219     0.480      0.660       **0.002**      0.978       0.440       0.107
  Free PCS      0.263       0.604     0.858    **0.007**     **0.050**      0.601       0.445     **0.036**
  Free PCG      0.205       0.763     0.409      0.070       **0.038**      0.777       0.300       0.317

Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric dimethylarginine, UA: uric acid, β~2~M: beta-2-microglobulin, HA: hippuric acid, IS: indoxyl sulfate, IAA: indole acetic acid, PCS: *p*-cresylsulfate, PCG: *p*-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.

BW: body weight, PNA: protein equivalent of nitrogen appearance, RRF: residual renal function, DM: diabetes mellitus.

P\<0.05 is indicated in bold.

[Table 4](#pone-0076838-t004){ref-type="table"} shows the R and P-values of the Spearman correlations between solute concentrations and patient characteristics. Kt/V~urea~ showed a correlation only with the concentration of Crea. PNA, on the contrary, showed significant correlations for the majority of solutes with R = 0.894 for urea, and a value in the range 0.4--0.6 for UA, PCS, and free PCS, and 0.2--0.4 for Crea, HA, IS, PCG, free HA, and free PCG. RRF showed inversed correlations with an R-value in the range −0.4 to −0.6 for β~2~M, HA, free HA, and free IAA, and with R between −0.2 and −0.4 for IS, PCG, free IS, free PCS, and free PCG.

10.1371/journal.pone.0076838.t004

###### P and R-values for Spearman correlations between the solute concentrations and the different patient characteristics.

![](pone.0076838.t004){#pone-0076838-t004-4}

                      Age          BW          Kt/V          PNA           RRF        vintage
  ---------- --- ------------- ----------- ------------ ------------- ------------- ------------
  urea        P    **0.007**      0.511       0.230      **\<0.001**      0.561        0.210
              R   **−0.320**                              **0.894**                 
  Crea        P    **0.009**    **0.009**   **0.048**     **0.004**       0.207        0.332
              R   **−0.311**    **0.312**   **−0.237**    **0.336**                 
  ADMA        P      0.657        0.880       0.118         0.577         0.608        0.950
  SDMA        P      0.552        0.962       0.160         0.211         0.427        0.470
  UA          P   **\<0.001**   **0.041**     0.058       **0.001**       0.243      **0.007**
              R   **−0.446**    **0.256**                 **0.373**                  **−0.336**
  β~2~M       P      0.913        0.837       0.742         0.506      **\<0.001**     0.305
              R                                                        **−0.415**   
  HA          P      0.962        0.490       0.668       **0.005**    **\<0.001**     0.232
              R                                           **0.330**    **−0.431**   
  IS          P      0.967        0.196       0.801       **0.046**     **0.022**      0.282
              R                                           **0.237**    **−0.272**   
  IAA         P      0.658        0.602       0.140         0.801         0.101        0.782
  PCS         P      0.456        0.941       0.712      **\<0.001**      0.829        0.809
              R                                           **0.529**                 
  PCG         P      0.825        0.734       0.651       **0.003**     **0.004**      0.540
              R                                           **0.349**    **−0.335**   
  CMPF        P    **0.003**      0.154       0.576         0.562         0.080        0.559
              R    **0.346**                                                        
  Free HA     P      0.840        0.398       0.824       **0.024**    **\<0.001**     0.229
              R                                           **0.267**    **−0.453**   
  Free IS     P      0.953        0.361       0.870         0.131       **0.001**      0.668
              R                                                        **−0.380**   
  Free IAA    P      0.964        0.451       0.084         0.525      **\<0.001**     0.653
              R                                                        **−0.410**   
  Free PCS    P      0.959        0.612       0.664      **\<0.001**    **0.028**      0.238
              R                                           **0.445**    **−0.261**   
  Free PCG    P      0.792        0.746       0.639       **0.003**     **0.004**      0.536
              R                                           **0.346**    **−0.337**   

Crea: creatinine, ADMA: asymmetric dimethylarginine, SDMA: symmetric dimethylarginine, UA: uric acid, β~2~M: beta-2-microglobulin, HA: hippuric acid, IS: indoxyl sulfate, IAA: indole acetic acid, PCS: *p*-cresylsulfate, PCG: *p*-cresylglucuronide, CMPF: 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.

BW: body weight, PNA: protein equivalent of nitrogen appearance, RRF: residual renal function.

P\<0.05 is indicated in bold. R values only shown in case of significant P.

Also in multifactor analysis, PNA and RRF were the main factors associated with uremic solute concentration, except for Crea, and this occurred mainly independently ([Table 5](#pone-0076838-t005){ref-type="table"}).

10.1371/journal.pone.0076838.t005

###### Multifactor analysis: covariates with cumulative R-value.
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  Solute      Covariates/R-value of full model  
  ---------- ---------------------------------- ------------
  Urea                   PNA/0.894              
  Crea                   PNA/0.336               Kt/V/0.624
  ADMA                                          
  SDMA                                          
  UA                     PNA/0.373              
  β~2~M                  RRF/−0.415             
  HA                     RRF/−0.431             
  IS                     RRF/−0.272             
  IAA                                           
  PCS                    PNA/0.529              
  PCG                    PNA/0.349               RRF/0.441
  CMPF                   age/0.346              
  Free HA                RRF/−0.453             
  Free IS                RRF/−0.380             
  Free IAA               RRF/−0.410             
  Free PCS               PNA/0.445              
  Free PCG               PNA/0.346               RRF/0.438

Empty cells indicate that the correlation analysis did not include other elements that contributed significantly.

Discussion {#s4}
==========

In a group of 71 hemodialysis patients, variances were studied for a broad range of predialysis uremic toxin concentrations as functions of different patients characteristics and Kt/V~urea~. The most important findings are that different quartiles of Kt/V~urea~ did not show any variations in serum concentration of the studied solutes, whereas quartiles of PNA and RRF showed significant variations of serum levels for 6 and 8 solutes under study, respectively. For correlation analysis, only one association was found for Kt/V~urea~, whereas there were 10 associations for PNA and 9 for RRF, pointing into the same direction as the analysis per quartiles.

UA, ADMA, PCS, IS, and β~2~M have repeatedly been associated with vascular damage and mortality in renal and general populations [@pone.0076838-Bammens1]--[@pone.0076838-Cheung2]. In our study, quartiles of weekly Kt/V~urea~ did not show any significant variance in serum concentration of these solutes as was also found for spKt/V and eKt/V (data not shown). The weekly Kt/V~urea~, per definition accounting for RRF, was correlated to only one investigated solute concentration, while no correlations were found when considering spKt/V or eKt/V (data not shown). On the other hand, subdivision for quartiles of PNA showed differences in the serum concentration of UA, PCS, urea, Crea, HA, and free PCS, and showed, additionally, correlations with the concentrations of IS, PCG, free HA, and free PCG. Furthermore, quartiles of RRF showed differences for β~2~M, HA, PCG, and free concentrations of HA, IS, IAA, PCS, and PCG, and showed, additionally, correlations with the IS concentrations. Hence, from the present study, Kt/V~urea~ does not seem to be a very good predictor of uremic solute concentrations, not even in the subpopulation of patients without any residual renal function (data not shown).

During the last decade, it became clear that dialysis dose, as measured by the removal of a low-molecular weight solute such as urea as is the case with Kt/V~urea~, may not entirely be a parameter of dialysis adequacy. Kinetics of urea differ from that of other uremic solutes, even when these are small and water soluble like urea is [@pone.0076838-Eloot4], [@pone.0076838-Eloot5]. Furthermore, increasing dialysis time from 4 up to 8 hours, without changing the quantity of processed blood and dialysate, did not impact Kt/V~urea~, whereas, β~2~M, a middle molecule and phoshate, a small but difficult to remove solute, showed an increase by 81 and 49% respectively [@pone.0076838-Eloot1]. The present study here adds that not only solute removal but also predialysis solute concentration is not reflected in Kt/V~urea~. At first sight, this could be an evident conclusion, since Kt/V~urea~ is mathematically related to the change in urea concentration during dialysis rather than to the absolute concentration. However, the ultimate goal of hemodialysis is to decrease absolute toxic solute concentrations, and with it, the biological activity of uremic toxins. Hence, keeping the adequacy parameter Kt/V~urea~ above the prescribed threshold should result in decreased concentrations.

Fairly similar deceiving results, pleading against a unique universal marker of uremic solute removal, were obtained in two recent studies evaluating the associations of uremic retention solute concentrations with estimated Glomerular Filtration Rates (eGFR) in patients of Chronic Kidney Disease (CKD) stage 2 to 5, not on dialysis [@pone.0076838-Eloot3], [@pone.0076838-Neirynck1]. These data strongly suggest that other factors than GFR are more powerful determinants of serum solute concentration [@pone.0076838-Eloot3]. These include renal tubular secretion (IS, HA) [@pone.0076838-BoumendilPodevin1], metabolic factors (ADMA) [@pone.0076838-Spoto1], intestinal secretion, absorption and generation (UA) [@pone.0076838-Vaziri1], (indoles, phenols) [@pone.0076838-Schepers1], [@pone.0076838-Guarner1], [@pone.0076838-Aronov1], (IS) [@pone.0076838-Kusumoto1], [@pone.0076838-Swann1].[@pone.0076838-Eloot3], [@pone.0076838-Fujita1], [@pone.0076838-Heinzmann1]. Impressive differences in serum concentration of different solutes, either adjusted or not for Kt/V~urea~, were found in our present study (ranging from 72 to close to 100%), confirming previous data in another hemodialyzed population (concentration differences ranging from 66 to 100%) [@pone.0076838-Eloot3], so that the same interfering factors may also play an as important role in dialysis patients as in non-dialyzed CKD patients.

We found that residual renal function (RRF) distinguishes well among solute concentrations. This confirms previous findings that RRF has a higher impact on patient outcome than a high delivered Kt/V~urea~ [@pone.0076838-Krediet1], and that RRF is better associated with optimal nutritional status than dialysis adequacy [@pone.0076838-Suda1]. In addition, even limited increments of RRF are substantially more important than dialyzer clearance as a determinant of β~2~M concentrations in patients on high flux hemodialysis [@pone.0076838-Evenepoel1] and even hemodiafiltration, in spite of enhanced β~2~M clearance with this strategy due to convection [@pone.0076838-Fry1], [@pone.0076838-Penne1]. Also for the protein bound compounds, RRF has a major contribution to total solute removal of patients on dialysis [@pone.0076838-Bammens2], [@pone.0076838-Marquez1].

The contribution of RRF to the differences between patients in the serum concentration of β~2~M is in correspondence with the inverse associations between RRF and another middle molecule, Fibroblast Growth Factor-23 (FGF23) as previously found in a prospective observational cohort study in peritoneal and hemodialysis patients [@pone.0076838-Viaene1].

Our findings for RRF as predictor for most uremic solute concentrations in the dialysis population do not fully match our previous findings for eGFR as predictor for solute concentrations in CKD 2--5 patients not on dialysis [@pone.0076838-Schwedler1]--[@pone.0076838-Suliman2]. This might be due to a difference in calculation of the renal function: i.e. while RRF in this study is assessed directly using concentrations of Crea and urea in blood and urine, in our previous studies eGFR was estimated only using blood concentrations of Crea and/or CystC [@pone.0076838-Schwedler1]--[@pone.0076838-Suliman2]. In addition, GFR in the present dialysis population is much lower than in the earlier CKD stages, whereas dialysis is an additional confounder affecting concentration. Thus conditions in between studies were entirely different.

Our data with regards to residual renal function point into the same direction as those recently reported by Marquez et al [@pone.0076838-Schwedler1]--[@pone.0076838-Suliman2], also showing inverse correlations between protein bound solute concentrations and residual renal function, even if they did not take into account a measure of protein intake such as PNA.

Regarding PNA, significant correlations were found with predialysis urea concentrations, as could be expected from the PNA formula ([equation 8](#pone.0076838.e008){ref-type="disp-formula"}). However, PNA is also well related to substantial differences in serum concentrations of many other solutes under study. These data are consistent with growing evidence that food protein intake and its intestinal processing, to a large extent regulated by the gut microbiota, plays an important role in uremic toxin generation, especially in relation with protein bound molecules derived from amino acid metabolites such as indole or p-cresol [@pone.0076838-Schepers1], [@pone.0076838-Bammens3], [@pone.0076838-Evenepoel2]. Of note, whereas quartiles of PNA showed variances in concentrations of solutes that are amino acid metabolites and thus depending on protein intake, this was not the case for β~2~M which, as a component of major histocompatibility complex class I molecules, is of endogenous origin.

Our data might seemingly be in contradiction with the current understanding that inadequate nutrition is an important predictor of outcome in chronic hemodialysis patients [@pone.0076838-Schulman1]--[@pone.0076838-Bergstrom1], since low values of PNA have been associated with higher morbidity and mortality [@pone.0076838-Acchiardo1], [@pone.0076838-Laird1] whereas here they are linked to lower uremic toxin concentrations. However, for several uremic retention solutes such as AGEs and Hcy, a low rather than high concentration has been associated with higher mortality in dialysis patients [@pone.0076838-Schwedler1]--[@pone.0076838-Suliman2]; these differences have been attributed to the fact that the toxic effect of the molecules was overridden by the deleterious impact of malnutrition and the lower intake of solutes or their precursors when less food is entering the intestine [@pone.0076838-Schwedler1], [@pone.0076838-Suliman1]. For protein bound toxins, like indoxyl sulfate or p-cresylsulfate, however, high, not low, concentration has repeatedly been associated with mortality, even after adjustment for protein intake parameters [@pone.0076838-Bammens1], [@pone.0076838-Barreto1], [@pone.0076838-Liabeuf1], suggesting that toxin concentration in this case overrides the impact of nutrition on outcome. This does not take away that low protein intake should be avoided in hemodialysis patients due to its negative impact on outcome per se [@pone.0076838-Bergstrom1], [@pone.0076838-Acchiardo1]. Our data do not refute high protein intakes but are only proof of concept that the intestinal protein load is an important source of uremic toxins, and that therapeutic means to reduce this (probiotics, prebiotics, sorbents), if they are not jeopardizing nutritional status, may have added value to the removal obtained by dialysis and should be explored and assessed in controlled trials.

Furthermore, PNA is not only a nutrition term but is also influenced by the metabolic status of the patient. Examination of the body weights during a period starting one month before until one month after the study reveals however that 35% of the patients are stable in weight, while only minor changes (1.8%) were seen in the remaining group with a comparable number of patients with increasing and decreasing body weight, respectively \[69.0 (61.3--78.8) kg\]. Hence, changes in metabolic status in our patient population did not influence correlations between PNA and uremic toxin concentrations.

A small number of studies suggested that PNA linearly varies with the dialysis dose Kt/V~urea~ [@pone.0076838-Lindsay1], [@pone.0076838-Azar1], but the HEMO study failed to demonstrate any significant change in protein intake attributable to hemodialysis dose [@pone.0076838-Rocco2]. The present study as well did not find any correlation between PNA and Kt/V~urea~ (data not shown).

Strengths of this study are the assessment of a population from one single unit where the same standards of treatment are applied overall, and the inclusion of several parameters with the potential impact on solute concentration. A shortcoming of this study is its transversal nature with only one set of values per patient at one single moment. However, an analysis using average Kt/V~urea~ of the same population over a period of 3 months resulted in the same conclusions (data not shown). In addition, single values of PNA and RRF were used which nevertheless resulted in much higher variances. An analysis using average PNA of the same population over a period of 3 months resulted in even more correlations with uremic toxin concentrations (i.e. also correlated with free IS and free IAA concentrations). Another shortcoming might have been the use of predialysis uremic toxin concentrations. However, an analysis using the time averaged concentration (TAC) of urea, the only solute of which the post dialysis value was available to calculate TAC, gave similar results. Finally, the study results for PNA could have been skewed by not considering the urea concentration after post-dialysis rebound [@pone.0076838-Stegeman1] and by only looking at a midweek dialysis session possibly overestimating the weekly value [@pone.0076838-Lopot1] and not including intraweek variability [@pone.0076838-Kloppenburg1]. However, since overestimations by not considering urea rebound are only in the range of 6% [@pone.0076838-Stegeman1], since we considered midweek sessions with similar dialysis durations (245±18 min) which were constant during the preceding three months, and since intraweek variations (estimated being 9.3% [@pone.0076838-Kloppenburg1]) are likely to be counterbalanced among patients, our correlation analyses between PNA and uremic toxin concentrations can be considered representative.

Conclusion {#s5}
==========

In conclusion, serum concentrations of most uremic toxins are correlated with residual renal function and protein equivalent of nitrogen appearance, and not with dialysis adequacy as assessed by Kt/V~urea~. Hence, we conclude from this observational study that efforts to control intestinal load of uremic toxin precursors by dietary or other interventions, and preserving RRF are important approaches to decrease uremic solute concentration and by extension their toxicity.
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